Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Maximilian Koch; Johannes S de Jong; Jürgen Glatz; Panagiotis Symvoulidis; Laetitia E Lamberts; Arthur L. L. Adams; Mariëtte E G Kranendonk; Anton G T Terwisscha van Scheltinga; Michaela Aichler; Liesbeth Jansen; Jakob de Vries; Marjolijn N Lub-de Hooge; Carolien P. Schröder; Annelies Jorritsma-Smit; Matthijs D Linssen; Esther de Boer; Bert van der Vegt; Wouter B Nagengast; Sjoerd G Elias; Sabrina Oliveira; Arjen J. Witkamp; Willem P Th M Mali; Elsken van der Wall; Beatriz P Garcia-Allende; Paul J van Diest; Elisabeth G de Vries; Axel Walch; Gooitzen M van Dam; Vasilis Ntziachristos

doi:10.1117/12.2286062

Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Maximilian Koch, Johannes S de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E Lamberts, Arthur L. L. Adams, Mariëtte E G Kranendonk, Anton G T Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D Linssen, Esther de Boer, Bert van der Vegt, Wouter B Nagengast, Sjoerd G Elias, Sabrina OliveiraArjen J. Witkamp, Willem P Th M Mali, Elsken van der Wall, Beatriz P Garcia-Allende, Paul J van Diest, Elisabeth G de Vries, Axel Walch, Gooitzen M van Dam, Vasilis Ntziachristos

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Original language	English
Journal	Proceedings of SPIE
Volume	10411
DOIs	https://doi.org/10.1117/12.2286062
Publication status	Published - 1 Jul 2017

Access to Document

10.1117/12.2286062

http://adsabs.harvard.edu/abs/2017SPIE10411E..0FK

Cite this

Koch, M., de Jong, J. S., Glatz, J., Symvoulidis, P., Lamberts, L. E., Adams, A. L. L., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Aichler, M., Jansen, L., de Vries, J., Lub-de Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., de Boer, E., van der Vegt, B., Nagengast, W. B., Elias, S. G., ... Ntziachristos, V. (2017). Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold. Proceedings of SPIE , 10411. https://doi.org/10.1117/12.2286062

@article{e3b093533cd14f36af7b4897b5e59ee3,

title = "Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold",

abstract = "In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.",

author = "Maximilian Koch and {de Jong}, {Johannes S} and J{\"u}rgen Glatz and Panagiotis Symvoulidis and Lamberts, {Laetitia E} and Adams, {Arthur L. L.} and Kranendonk, {Mari{\"e}tte E G} and {Terwisscha van Scheltinga}, {Anton G T} and Michaela Aichler and Liesbeth Jansen and {de Vries}, Jakob and {Lub-de Hooge}, {Marjolijn N} and Schr{\"o}der, {Carolien P.} and Annelies Jorritsma-Smit and Linssen, {Matthijs D} and {de Boer}, Esther and {van der Vegt}, Bert and Nagengast, {Wouter B} and Elias, {Sjoerd G} and Sabrina Oliveira and Witkamp, {Arjen J.} and Mali, {Willem P Th M} and {van der Wall}, Elsken and Garcia-Allende, {Beatriz P} and {van Diest}, {Paul J} and {de Vries}, {Elisabeth G} and Axel Walch and {van Dam}, {Gooitzen M} and Vasilis Ntziachristos",

year = "2017",

month = jul,

day = "1",

doi = "10.1117/12.2286062",

language = "English",

volume = "10411",

journal = "Proceedings of SPIE ",

issn = "0277-786X",

publisher = "SPIE",

}

Koch, M, de Jong, JS, Glatz, J, Symvoulidis, P, Lamberts, LE, Adams, ALL, Kranendonk, MEG, Terwisscha van Scheltinga, AGT, Aichler, M, Jansen, L, de Vries, J, Lub-de Hooge, MN, Schröder, CP, Jorritsma-Smit, A, Linssen, MD, de Boer, E, van der Vegt, B, Nagengast, WB, Elias, SG, Oliveira, S, Witkamp, AJ, Mali, WPTM, van der Wall, E, Garcia-Allende, BP, van Diest, PJ, de Vries, EG, Walch, A, van Dam, GM & Ntziachristos, V 2017, 'Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold', Proceedings of SPIE , vol. 10411. https://doi.org/10.1117/12.2286062

TY - JOUR

T1 - Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

AU - Koch, Maximilian

AU - de Jong, Johannes S

AU - Glatz, Jürgen

AU - Symvoulidis, Panagiotis

AU - Lamberts, Laetitia E

AU - Adams, Arthur L. L.

AU - Kranendonk, Mariëtte E G

AU - Terwisscha van Scheltinga, Anton G T

AU - Aichler, Michaela

AU - Jansen, Liesbeth

AU - de Vries, Jakob

AU - Lub-de Hooge, Marjolijn N

AU - Schröder, Carolien P.

AU - Jorritsma-Smit, Annelies

AU - Linssen, Matthijs D

AU - de Boer, Esther

AU - van der Vegt, Bert

AU - Nagengast, Wouter B

AU - Elias, Sjoerd G

AU - Oliveira, Sabrina

AU - Witkamp, Arjen J.

AU - Mali, Willem P Th M

AU - van der Wall, Elsken

AU - Garcia-Allende, Beatriz P

AU - van Diest, Paul J

AU - de Vries, Elisabeth G

AU - Walch, Axel

AU - van Dam, Gooitzen M

AU - Ntziachristos, Vasilis

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

AB - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

U2 - 10.1117/12.2286062

DO - 10.1117/12.2286062

M3 - Article

SN - 0277-786X

VL - 10411

JO - Proceedings of SPIE

JF - Proceedings of SPIE

ER -

Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Abstract

Access to Document

Fingerprint

Cite this